Utility of flow cytometry studies in the management of patients with multiple myeloma.
Paiva B et al. Curr Opin Oncol. 2016 Sep 12. [Epub ahead of print].

Minimal residual disease evaluation in autologous stem cell transplantation recipients with multiple myeloma.
Gupta R et al. Leuk Lymphoma. 2016 Sep 23:1-4. [Epub ahead of print].

Role of MRD status in relation to clinical outcomes in newly diagnosed multiple myeloma patients: a meta-analysis.
Landgren O et al. Bone Marrow Transplant. 2016 Sep 5. doi: 10.1038/bmt.2016.222. [Epub ahead of print].

Treatment response evaluation with 18F-FDG PET/CT and 18F-NaF PET/CT in multiple myeloma patients undergoing high-dose chemotherapy and autologous stem cell transplantation.
Sachpekidis C et al. Eur J Nucl Med Mol Imaging. 2016 Aug 29. [Epub ahead of print].

Use of Marrow Scintigraphy to Confirm Compensatory Marrow Rather than Active Myeloma.
Sahoo MK et al. World J Nucl Med. 2016 Sep;15(3):219-20. doi: 10.4103/1450-1147.189558.

Use of Marrow Scintigraphy to Confirm Compensatory Marrow Rather than Active Myeloma.
Bartel TB et al. World J Nucl Med. 2016 Sep;15(3):203-5. doi: 10.4103/1450-1147.172303.

Serum free immunoglobulin light chain fingerprint identifies a subset of newly diagnosed multiple myelomapatients with worse outcome.
Avivi I et al. Hematol Oncol. 2016 Sep 19. doi: 10.1002/hon.2336. [Epub ahead of print].

Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma: A Meta-analysis.
Munshi NC et al. JAMA Oncol. 2016 Sep 15. doi: 10.1001/jamaoncol.2016.3160. [Epub ahead of print].

Cerebrospinal Fluid Cytological Diagnosis in Multiple Myeloma With Leptomeningeal Involvement: A Report of Two Cases.
Ren H et al. Diagn Cytopathol. 2016 Sep 15. doi: 10.1002/dc.23600. [Epub ahead of print].

Quantitative Diffusion-weighted Imaging of the Bone Marrow: An Adjunct Tool for the Diagnosis of a Diffuse MR Imaging Pattern in Patients with Multiple Myeloma.
Koutoulidis V et al. Radiology. 2016 Sep 9:160363. [Epub ahead of print].

Prediction of peripheral neuropathy in multiple myeloma patients receiving bortezomib and thalidomide: a genetic study based on a single nucleotide polymorphism array.
García-Sanz R et al. Hematol Oncol. 2016 Sep 8. doi: 10.1002/hon.2337. [Epub ahead of print].

Development of a Fluorescent Labeling Reagent for Determination of Proline and Hydroxyproline in MyelomaPatient Plasma by HPLC-FLD.
Teng Z et al. J Chromatogr Sci. 2016 Sep 6. [Epub ahead of print].

Prognostic significance of focal lesions and diffuse infiltration on MRI for multiple myeloma: a meta-analysis.
Lee SY et al. Eur Radiol. 2016 Sep 5. [Epub ahead of print].

Cancer testis antigen MAGE C1 can be used to monitor levels of circulating malignant stem cells in the peripheral blood of multiple myeloma patients.
Shires K et al. J Cancer Res Clin Oncol. 2016 Aug 31. [Epub ahead of print].

Differentiation stage of myeloma plasma cells: biological and clinical significance.
Paiva B et al. Leukemia. 2016 Sep 16. doi: 10.1038/leu.2016.211. [Epub ahead of print].